Drug Production

Eli Lilly expanding its drug production for obesity and Alzheimer's treatment in Ireland

Eli Lilly is funding US$1.8 billion in manufacturing sites in Ireland to increase obesity drug production and treatment for Alzheimer's.

It is a part of Eli Lilly’s dedication to growing its manufacturing capacity, particularly for its leading-selling diabetes and obesity medications, Mounjaro and Zepbound.

Investment in Kinsale, Ireland

The firm announced that it has poured approximately US$800 million into its latest establishment in Kinsale, Ireland, which started producing Lilly's treatments for obesity and diabetes last year. The need for Zepbound has exceeded the available supply for much of this year.

The remaining funds will be allocated for the expansion of the drugmaker company's plant located in Limerick, Ireland, aimed at enhancing the production of active biologic components for specific medications, including Alzheimer's therapy.

Since the launch of Zepbound in December, Lilly has rapidly gained a market presence, reaching approximately 40% in the US. 

Eli Lilly’s Drugs for Alzheimer

In July, Lilly's drug for Alzheimer's got the green light in the US, and it's presently being examined by health authorities in Europe and the UK.

Novo Nordisk, a competitor of Danish firm Novo Nordisk (NOVOb.CO), has poured billions into expanding its production capabilities for its well-known weight loss drug, Wegovy. 

Since 2020, the firm has dedicated more than US$20 billion to construct and enlarge its production sites in the US and Europe.